MaxCyte, Inc. Common Stock
MXCTMaxCyte, Inc. is a global biotechnology company specializing in the development and commercialization of advanced cell engineering and transfection technologies. Its platform enables efficient, scalable, and reproducible modification of cells, supporting the development of cell-based therapies, research, and drug discovery. MaxCyte’s technology is widely used in immuno-oncology, gene editing, and regenerative medicine applications.
Company News
U.S. stock futures showed mixed performance on Wednesday with Dow Jones futures falling while S&P 500 and Nasdaq 100 rose. President Trump visited China with major tech leaders including Nvidia's Jensen Huang, Tesla's Elon Musk, and Apple's Tim Cook. Key movers included Nextpower surging on strong earnings, MaxCyte jumping on better-than-expected...
MaxCyte reported preliminary 2025 financial results with core revenue of $29.5-29.6 million for the full year, in line with guidance despite a challenging macro environment. The company ended the year with approximately $155.6 million in cash and investments, significantly reduced annual burn, and a restructured organization. Management expects t...
The global transfection technologies market is expected to grow at a CAGR of 9.0% from 2024 to 2032, driven by the rising demand for protein production and advancements in biotechnology.
The average of price targets set by Wall Street analysts indicates a potential upside of 85% in MaxCyte (MXCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
MaxCyte (MXCT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
